U.S. PRODUCERS' QUESTIONNAIRE

HARD EMPTY CAPSULES FROM BRAZIL, CHINA, INDIA, AND VIETNAM

This questionnaire must be received by the Commission by November 7, 2024

See last page for instructions regarding how to file this questionnaire.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its countervailing duty and antidumping investigations concerning HECs from Brazil, China, India, and Vietnam (Inv. Nos. 701-TA-742-745 and 731-TA-1720-1723 (Preliminary)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of firm

| | Address | | | | | | | |
|--|--|--|--|---|--|--|---|---|
| | City | | | State | Zip Code | e | | |
| | Website | | | | | | | |
| | Has your firm pr | oduced HEC | s (as defined on next | page) in the Uni | ted States at | any time since Janu | uary 1, 2021? | |
| | ■ NO (5 | Sign the certif | ication below and prom | nptly return only t | his page of the | questionnaire to the | Commission) | |
| | YES (| Complete all _I | parts of the questionnai | re, and return the | entire questio | nnaire to the Commi | ssion) | |
| | • | urn questionnaire via the Commission's secure portal by clicking on the following link: s://usitc.gov/qportal . (PIN: HECS). See last page for detailed instructions. | | | | | | |
| | | | CE | RTIFICATION | | | | _ |
| nowled neans on nforma | dge and belief and of this certification | understand 1 I also gra is questionr | supplied in respons that the information int consent for the naire and throughout merchandise. | n submitted is s Commission, a | ubject to aud nd its employ | it and verification vees and contract | by the Comm personnel, to | nission. By o use the |
| oroceed personn eviews, Appendi | ling or other proced rel (a) for developir , and evaluations ix 3; or (ii) by U.S. <u>(</u> | edings may ng or maint relating to government | information submit be disclosed to and aining the records of the programs, pers employees and cont e nondisclosure agre | used: (i) by the f this or a relate connel, and ope tract personnel, | Commission of the commission of the commission | , its employees ar g, or (b) in interna he Commission in | nd Offices, and Il investigation Icluding under | d contract ns, audits, r 5 U.S.C. |
| lame oj | f Authorized Officia | 11 | Title of Authorized O | fficial | | Date | | |
| ignature Phone | | | | | Email address | | | |

PART I.—GENERAL INFORMATION

Background.--This proceeding was instituted in response to a petition filed on October 24, 2024, by Lonza Greenwood LLC, Greenwood, South Carolina. Countervailing and/or antidumping duties may be assessed on the subject imports as a result of these proceedings if the Commission makes an affirmative determination of injury, threat, or material retardation, and if the U.S. Department of Commerce ("Commerce") makes an affirmative determination of subsidization and/or dumping. Pertinent information to this proceeding is available at:

Questionnaires: https://usitc.gov/reports/active import injury questionnaires. Other case information: https://ids.usitc.gov/case/8233/investigation/8646

<u>HECs</u> covered by this proceeding are hard empty capsules (HECs), which are unfilled cylindrical shells composed of at least 80 percent by weight of a non-toxic biodegradable, biocompatible, and water soluble polymer, and may also contain water, additives, opacifiers, colorants, and processing aids. HECs may also be imprinted or otherwise decorated with markings.

The most common polymer materials in HECs are gelatin derived from animal collagen (including, but not limited to, pig, cow, or fish collagen), hydroxypropyl methylcellulose (HPMC), and pullulan. However, HECs may also be made of other non-toxic, biodegradable, biocompatible, and water soluble polymer materials.

HECs are comprised of two prefabricated, hollowed cylindrical sections (cap and body). The cap and body pieces each have one closed and rounded end and one open end, and are constructed with different or equal diameters at their open ends.

HECs are covered by the scope of this investigation regardless of polymer material, additives, transparency, opacity, color, imprinting, or other markings.

HECs are also covered by the scope of this investigation regardless of their size, weight, length, diameter, thickness, and filling capacity.

Cap and body pieces of HECs are covered by the scope of this investigation regardless of whether they are imported together or separately, and regardless of whether they are imported in attached or detached form.

Products that do not disintegrate/dissolve in a liquid biorelevant medium (e.g., water) under tests specified in the United States Pharmacopeia – National Formulary (USP-NF), or equivalent disintegration/dissolution tests, within 2 hours are not covered by the scope of this investigation.

HECs are currently imported under statistical reporting numbers 9602.00.1040 or 9602.00.5010 of the Harmonized Tariff Schedule of the United States (HTSUS). In addition, gelatin HECs may be imported under HTSUS statistical reporting number 3503.00.5510; HPMC HECs may be imported under HTSUS statistical reporting number 3923.90.0080; and pullulan HECs may be imported under HTSUS statistical reporting number 2106.90.9998. The HTSUS provisions are for convenience and customs purposes; the written description of the scope is dispositive.

<u>1,000 units</u>.—Quantities in this questionnaire are requested to be reported in 1,000 units. For HECs, units represent an individual capsule or HEC. In other words, in a line requesting quantity data if your firm reports "20" that represents 20,000 individual capsules, and since in this industry a standard bag size contains 1,000 individual capsules, that reported "20" would represent 20 such bags with 1,000 capsules each. If your firm ships HECs in containers or bags other than bags containing 1,000 capsules,

please convert your quantities to the 1,000 unit equivalent when reporting quantity data in this questionnaire. For example, if your firm sold 100 bags containing 500 capsules each, your firm should report a quantity of 50 (i.e., 100 * 500 / 1000). Please do not report quantities in individual bags, eaches, or other such units of measure. Remember if your firm's records are not stored in the requested quantity measurement, carefully made estimates to convert your firm's data into the requested quantity measure are acceptable and then the use of such estimates should be noted in the catch all question at the end of each relevant section in this questionnaire where such estimates were reported. While capsules and units are sometimes used interchangeably, for the purposes of consistency we will be discussing volume in units.

<u>Reporting of information</u>.--If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals. In addition, if your firm is a U.S. producer, the information you provide on your production and imports of HECs and your responses to the questions in Part I of the producer questionnaire will be provided to the U.S. Department of Commerce, upon its request, for use in connection with (and only in connection with) its requirement pursuant to section 702(c)(4)/732(c)(4) of the Act (19 U.S.C. § 1671a(c)(4)/1673a(c)(4)) to make a determination concerning the extent of industry support for the petition requesting this proceeding. Any information provided to Commerce will be transmitted under the confidentiality and release guidelines set forth above. Your response to these questions constitutes your consent that such information be provided to Commerce under the conditions described above.

<u>D-GRIDS tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (https://www.usitc.gov/trade_remedy/question.htm) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is <u>optional</u>. Firms opting to use the D-GRIDs tool to populate their

data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

I-1a. Reporting requirements.--Please report below the actual number of hours required and the cost to your firm of completing this questionnaire for use by the Office of Management and Budget.

| Hours | Dollars |
|-------|---------|
| | |

Public reporting burden for this questionnaire is estimated to average 55 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please provide such comments to the Office of Investigations, import injury@usitc.gov.

| I-1b. | TAA information releaseIn the event that the U.S. International Trade Commission (USITC) |
|-------|--|
| | makes an affirmative final determination in this proceeding, do you consent to the USITC's |
| | release of your contact information (company name, address, contact person, contact person's |
| | title, telephone number, email address) appearing on the front page of this questionnaire to the |
| | Departments of Commerce, Labor, and Agriculture, as applicable, so that your firm and its |
| | workers can be made eligible for benefits under the Trade Adjustment Assistance program? |
| | |

| l l Yes I I N | | Yes | | \neg N |
|---------------|--|-----|--|----------|
|---------------|--|-----|--|----------|

I-2a. <u>Establishments covered</u>.--Provide the city, state, zip code, and brief description of each establishment covered by this questionnaire. Firms operating more than one establishment should combine the data for all establishments into a single report.

"<u>Establishment</u>"--Each facility of a firm involved in the <u>production</u> of HECs, including auxiliary facilities operated in conjunction with (whether or not physically separate from) such facilities.

| Establishments covered ¹ | City, State | Zip (5 digit) | Description |
|--|-------------|---------------|-------------|
| 1 | | | |
| 2 | | | |
| 3 | | | |
| 4 | | | |
| 5 | | | |
| 6 | | | |
| ¹ Additional discussion on establishments consolidated in this questionnaire: | | | |

| | | · —— | | | |
|-------|--|--|--|--|--|
| I-2b. | <u>Stock symbol information.</u> If your firm or parent firm is publicly traded, please specify the stock exchange and trading symbol: | | | | |
| l-2c. | | your firm or parent firm is represented by external counsel in relation to se specify the name of the law firm and the lead attorney(s). | | | |
| | Law firm: | | | | |
| | Lead attorney(s): | | | | |

I-3. <u>Petitioner status.</u>--Is your firm a petitioner in this proceeding or a member firm of the petitioning entity?

| No | Yes |
|----|-----|
| | |

I-4. **Petition support**.--Does your firm support or oppose the petition?

| Country | Investigation type | Support | Oppose | Take no position |
|---|---------------------|---------|------------------------|------------------|
| Brazil | Antidumping duty | | | |
| Brazil | Countervailing duty | | | |
| China | Antidumping duty | | | |
| China | Countervailing duty | | | |
| India | Antidumping duty | | | |
| India | Countervailing duty | | | |
| Vietnam | Antidumping duty | | | |
| Vietnam | Countervailing duty | | | |
| I-5. OwnershipIs your firm owned, in whole or in part, by any other firm? | | | | |
| □ No | □ Voc Liet the fe | | ralating to the ultima | to manaat/aaa |

| OwnershipIs your firm owned | , in whole or in part, by any other firm? | |
|--|---|-------------------------------|
| ☐ No ☐ YesList the following information, relating to the ultimate parent/owner. | | |
| Firm name | Country | Extent of ownership (percent) |
| | | |
| | | |
| | | |

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

| No Yes | List the following information. | |
|-----------------------|---|---------------------------------|
| Firm name | Country | Affiliation |
| | | |
| | | |
| | | |
| engaged in the produc | | ms, either domestic or foreign, |
| engaged in the produc | ion of HECs?List the following information. | |
| engaged in the produc | cion of HECs? | ms, either domestic or foreign, |
| engaged in the produc | ion of HECs?List the following information. | |
| engaged in the produc | ion of HECs?List the following information. | |
| engaged in the produc | ion of HECs?List the following information. | |
| engaged in the produc | ion of HECs?List the following information. | |

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Julie Duffy (202-708-2579, Julie.duffy@usitc.gov). **Supply all data requested on a <u>calendar-year</u> basis**.

II-1. <u>Contact information.</u>--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in Part II.

| Name | |
|-----------|--|
| Title | |
| Email | |
| Telephone | |

II-2a. <u>Changes in operations.</u>—Please indicate whether your firm has experienced any of the following changes in relation to the production of HECs since January 1, 2021.

| | | If checked, please describe the nature, timing / duration, and impact on operations of any such reported changes as well as the business reasons for them; leave completely blank if not applicable |
|--|--|---|
| | Plant openings | |
| | Plant closings | |
| | Prolonged shutdowns | |
| | Production curtailments | |
| | Relocations | |
| | Expansions | |
| | Acquisitions | |
| | Consolidations | |
| | Weather-related or force majeure events | |
| | Other (e.g., revised labor agreements, technology) | |

II-2b. **COVID-19 pandemic.**—Has the COVID-19 pandemic or have any government actions taken to contain the spread of the COVID-19 virus resulted in changes in your firm's supply chain arrangements, production, employment, and shipments relating to HECs? In your response, please discuss the duration and timing of any such changes as they relate to your firm's operations.

| No | Yes | If yes, describe these changes including the impact over time on the (a) supply chain, (b) production and shipments, and (c) employment with respect to HECs. |
|----|-----|---|
| | | |

II-3a. **Production using same machinery.--**Please report your firm's production of products using the same equipment, machinery, or employees as used to produce HECs, and the combined capacity (both installed and practical capacity) on this shared equipment, machinery, or employees in the periods indicated.

"Installed overall capacity" – The level of production that your establishment(s) could have attained, assuming your firm's optimal product mix, and based solely on existing capital investments, i.e., machinery and equipment that is in place and ready to operate. This capacity measure does <u>not</u> take into account other constraints to production such as existing workforce constraints, availability of raw materials, or downtime for maintenance, repair, and clean-up. This capacity measure is sometimes referred to as "nameplate" or "theoretical" capacity.

"Practical overall capacity" – The level of production that your establishment(s) could reasonably have expected to attain, taking into account your firm's actual product mix over the period. This capacity measure is based on not only existing capital investments, i.e., machinery and equipment that is in place and ready to operate; but also non-capital investment constraints, such as (1) normal operating conditions, including normal downtime for maintenance, repair, and cleanup; (2) your firm's existing in place and readily available labor force; (3) availability of material inputs; and (4) any other constraints that may have limited your firm's ability to produce the reported products. Importantly, this capacity measure is the maximum "practical" production your firm could have achieved without hiring new personnel or expanding the number of shifts operated in the period.

"Practical HECs capacity" – The level of production of HECs that your establishment(s) could reasonably have expected to attain. The same assumptions apply to this capacity measure as for practical overall capacity, but only includes the portion of practical overall capacity allocated to the production of HECs based on the actual product mix experienced over the period.

"**Production**" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

| Takes into account | Installed overall capacity | Practical overall capacity | Practical HECs capacity |
|---|----------------------------|----------------------------|-------------------------|
| Existing capital investments | Yes | Yes | Yes |
| Product mix | Yes | Yes | Yes |
| Normal downtime, maintenance, repair and clean-up | No | Yes | Yes |
| Existing labor force | No | Yes | Yes |
| Availability of material inputs | No | Yes | Yes |
| Actual number of shifts and hours operated | No | Yes | Yes |
| Limited to HECs | No | No | Yes |

II-3a. **Production using same machinery.**—**Continued**

| Quantity (in 1,000 units) | | | | | |
|--|----------------------------|------|------|--------|------|
| | Calendar year January-June | | | y-June | |
| ltem | 2021 | 2022 | 2023 | 2023 | 2024 |
| Capacity measures: Installed overall capacity ¹ | | | | | |
| Practical overall capacity ¹² | | | | | |
| Practical HECs capacity ^{3 4} | 0 | 0 | 0 | 0 | 0 |
| Production of: HECs ^{3 4} | 0 | 0 | 0 | 0 | 0 |
| Out-of-scope products ⁵ | | | | | |
| Total production using same machinery or | | | _ | _ | _ |
| workers | 0 | 0 | 0 | 0 | 0 |

¹ Data reported for both "installed overall" and "practical overall" capacity should each individually be greater than data reported for total production (last line). Additionally, data reported for "installed overall" capacity should be greater than "practical overall" capacity in every period.

II-3b. **Operating parameters.--**The *practical* overall capacity reported in II-3a is based on the following operating parameters:

| Hours per week | Weeks per year |
|----------------|----------------|
| | |

| II-3c. | <u>Capacity calculations.</u> Please describe the methodology used to calculate <i>installed</i> and <i>practical</i> overall production capacities reported in II-3a, and explain any changes in reported capacities. |
|--------|--|
| | |

² Please provide details in your response to the question on capacity constraints in question II-3d below that explain the differences reported between "installed" overall capacity and "practical" overall capacity.

³ Data for this indicator will populate here once reported below in question II-8.

⁴ Data reported for practical HECs capacity should be greater than the data reported for production of HECs in each period, if not revise prior to submission to the Commission. Additionally, if your firm reports the production of no other products on the same machinery and using the same workers as HECs then "practical overall" and "practical HECs" capacity measures should be equal to each other.

⁵ Please identify these products: _____.

II-3d. Practical overall capacity constraints.--Please describe the constraint(s) that set the limit(s) on your firm's practical overall capacity over the period reported in question II-3a. If different constraints were binding over different periods reported, please specify when each constraint was limiting your reported practical overall capacity. If a constraint was not actually binding over the period reported, but was still a constraint to achieving the installed capacity level, indicate at what level it would have been binding.

| Constraint (check as many as appropriate) | | Description (If checked, please describe the details, timing, and duration of the constraint; leave completely blank if not applicable) |
|--|--|--|
| | Production bottlenecks | |
| | Existing labor force | |
| | Supply of material inputs | |
| | Fuel or energy | |
| | Storage capacity | |
| | Logistics/transportation | |
| | Other constraints (list the specific constraints in the description field) | |

| U.S. Pı | roducers' | Questionna | re - Hard Empty Capsules (Preliminary) | Page 14 |
|---------|-------------------------------|------------------------------|--|---------------------------------------|
| II-3e. | and the procuri | e additional a | overall capacityPlease describe and quantify the amount of actions that would be needed (e.g., hiring new workers, expaurces of raw material supply, etc.) for your firm to be able to verall capacity reported in II-3a. | nding shifts, |
| II-3f. | overall of prod capacit | capacity, ple uction) wou | erall capacityTo the extent that your company is reporting case report, with specificity: (1) which machines or equipmer ld need to be brought back into production for your plant to e specific dates on which such machines or equipment were ECs. | nt (or other elements operate at full |
| | | | | |
| II-4. | <u>Produc</u> | t shifting.— | | |
| | (a) | - | able to switch production (capacity) between HECs and other ment and/or labor? | er products using the |
| | No | Yes | If yes—(i.e., have produced other products or are able to products) Please identify other actual or potential products | |
| | | | | |
| | (b) | (e.g., time, | ribe the factors that affect your firm's ability to shift capacity cost, relative price change, etc.), and the degree to which the such shifts. | • |

| II-5. | Capacity checklistPlease check that the capacity numbers reported in question II-3a follow the |
|-------|--|
| | Commission's relevant definitions for capacity. |

| Item | √ if Yes |
|--|----------|
| Are all three capacity measures reported based on <u>currently installed</u> <u>machinery and equipment</u> (i.e., the reported capacity level would not require additional capital investments in order to achieve)? | |
| Are practical overall capacity and practical HECs capacity measures reported based on <u>existing labor force</u> (i.e., the reported capacity level would not require hiring additional production related workers or adding shifts)? | |
| Are practical overall capacity and practical HECs capacity measures based on the actual availability of material inputs? | |
| Do both practical overall capacity and practical HECs capacity measures account for <u>normal downtime</u> , <u>maintenance</u> , <u>repair and clean-up</u> activities? | |
| Does the difference between practical overall capacity and practical HECs capacity equal the portion of practical overall capacity that is dedicated to the production of out-of-scope products? | |

Note: If your firm is not able to answer "yes" to any of the above criteria as it relates to your firm's reported capacity levels, please revise your capacity numbers to be in conformance with the appropriate definition prior to submission to the Commission.

II-6. <u>Tolling</u>.--Since January 1, 2021, has your firm been involved in a toll agreement regarding the production of HECs?

"Toll agreement"-- Agreement between two firms whereby the first firm ("tollee") furnishes the raw materials and the second firm ("toller") uses the raw materials to produce a product that it then returns to the first firm with a charge for processing costs, overhead, etc.

| No | Yes | |
|----|-----|---|
| | | If yes—Please complete the table below. |

| Does your firm act as the toller or tollee in this arrangement? | Toller: | Tollee: |
|--|-----------------|---------|
| Report the share of your firm's production of HECs that was include arrangement in 2023. | ed in this toll | % |
| Please describe the activities performed in this tolling arrangement | : | |
| Please indicate the name(s) of the firm(s) involved: | | |

| II-7. Foreign trade zone |
|--------------------------|
|--------------------------|

(a) <u>Firm's FTZ operations</u>.--Does your firm produce HECs in and/or admit HECs into a foreign trade zone (FTZ)?

"Foreign trade zone" is a designated location in the United States where firms utilize special procedures that allow delayed or reduced customs duty payments on foreign merchandise. A foreign trade zone must be designated as such pursuant to the rules and procedures set forth in the Foreign-Trade Zones Act.

| No | If yesDescribe the nature of your firm's operations in FTZs and identify the specific FTZ site(s). |
|----|--|
| | |

(b) Other firms' FTZ operations.--To your knowledge, do any firms in the United States import HECs into a foreign trade zone (FTZ) for use in distribution of HECs and/or the production of downstream articles?

| No | Yes | If yesIdentify the firms and the FTZs. |
|----|-----|--|
| | | |

II-8. **Production, shipments, and inventory data.--**Report your firm's practical capacity, production, shipments, and inventories of domestically produced HECs during the specified periods.

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

"Commercial U.S. shipments" – Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments" – Shipments to destinations outside the United States, including shipments to related firms.

"Inventories" — Finished goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-8. Production, shipment, and inventory data.--Continued

| Quantity | | s) and value (i | n \$1,000) | T | |
|---|------|-----------------|------------|--------------|------|
| | - | Calendar year | , | January-June | |
| Item | 2021 | 2022 | 2023 | 2023 | 2024 |
| Practical HECs capacity¹ (quantity) (A) | | | | | |
| Beginning-of-period inventories (quantity) (B) | | | | | |
| Production (quantity) (C) | | | | | |
| U.S. shipments: Commercial shipments: Quantity (D) | | | | | |
| Value (E) | | | | | |
| Internal consumption: ² Quantity (F) | | | | | |
| Value² (G) | | | | | |
| Transfers to related firms: ² Quantity (H) | | | | | |
| Value² (I) | | | | | |
| Export shipments: ³ Quantity (J) | | | | | |
| Value (K) | | | | | |
| End-of-period inventories (quantity) (L) | | | | | |

² Internal consumption and transfers to related firms must be valued at fair market value. If your firm uses a different basis for valuing these transactions in your records, please specify that basis (e.g., cost, cost plus, *etc.*):

______. However, the data provided above in this table should be based on fair market value.

<u>RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY</u>.--Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

| | Calendar year | | | January-June | |
|--|---------------|------|------|--------------|------|
| Reconciliation | 2021 | 2022 | 2023 | 2023 | 2024 |
| B + C - D - F - H - J - L = should equal zero ("0") or provide an | | | | | |
| explanation. ¹ | 0 | 0 | 0 | 0 | 0 |

¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:_____.

³ Identify your firm's principal export markets: _____

II-9a. <u>Channels of distribution</u>.--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S. produced HECs by channel of distribution during the specified periods.

| Quantity (in 1,000 units) | | | | | |
|---------------------------------------|---------------|------|------|--------------|------|
| | Calendar year | | | January-June | |
| ltem | 2021 | 2022 | 2023 | 2023 | 2024 |
| U.S. shipments: | | | | | |
| to Distributors and/or retailers (M) | | | | | |
| to Pharmaceutical end users (N) | | | | | |
| to Nutraceutical end users (O) | | | | | |
| to Other end users¹ (P) | | | | | |
| ¹ Identity other end users | | | | | |

<u>RECONCILIATION OF CHANNELS</u>.--Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the quantity reported for U.S. shipments (i.e., line D, F, H) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | | January-June | |
|--|---------------|------|------|--------------|------|
| Reconciliation | 2021 | 2022 | 2023 | 2023 | 2024 |
| M + N + O + P - D - F - H = zero ("0"), if | | | | | |
| not revise. | 0 | 0 | 0 | 0 | 0 |

II-9b. <u>U.S. shipments by type:</u>.--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S. produced HECs by type during 2023.

| Quantity (in 1,000 units) | | | | |
|---------------------------|---------------|--|--|--|
| | Calendar year | | | |
| Item | 2023 | | | |
| U.S. shipments of HECs: | | | | |
| Gelatin (Q) | | | | |
| Non gelatin (R) | | | | |

<u>RECONCILIATION OF U.S. SHIPMENTS.</u>--Please ensure that the quantities reported for U.S. shipments by type (i.e., lines Q and R) in 2023 equal the quantity reported for U.S. shipments (i.e., line D, F, H) in 2023 in part "a" of this question. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year |
|--|---------------|
| Reconciliation | 2023 |
| Q + R - D - F - H = zero ("0"), if not revise. | 0 |

II-10. <u>Employment data</u>.--Report your firm's employment-related data related to the production of HECs in your U.S. establishment and provide an explanation for any trends in these data.

"Production and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary production for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above production operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12. For the January to June periods, calculate similarly and divide by 6.

If your firm had the same number of PRWs in all calendar year and had not experienced any changes in PRWs in the most recent interim period, you would have the same number of PRWs for the interim periods, regardless of whether the interim periods are Jan-Mar (Q1), Jan-June (Q1+Q2), or Jan-Sept (Q1+Q2+Q3)."

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

| | Calendar year | | | January-June | |
|------------------------------------|---------------|------|------|--------------|------|
| Item | 2021 | 2022 | 2023 | 2023 | 2024 |
| Average number of PRWs (number) | | | | | |
| Hours worked by PRWs (1,000 hours) | | | | | |
| Wages paid to PRWs (\$1,000) | | | | | |

Explanation of trends:

| <u>Transfers to related firms</u> If your firm reported transfers to related firms in question II-8, please identify the firm(s) and indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm. |
|---|
| |

| II-12. | <u>Purchases</u> Has your firm purchased HECs produced in the United States or in other countries |
|--------|---|
| | since January 1, 2021? (Do not include imports for which your firm was the importer of record. |
| | These should be reported in an importer questionnaire.) |

"Purchase" – A transaction to buy product from a U.S. corporate entity such as another U.S. producer, a U.S. distributor, or a U.S. firm that has directly imported the product.

"Import" —A transaction to buy from a foreign supplier where your firm is the importer of record.

| No | If yesReport such purchases in the table below and explain the reasons for your firms' purchases. |
|----|---|
| | |

Note: If your firm served as the importer of record for any purchases from foreign suppliers, either for your own account or as a service for another entity, those purchases are to be considered "imports" not "purchases" and **should not** be included in the table below

| | (Quantity in | 1,000 units) | | | |
|---|---------------|--------------|------|--------------|------|
| | Calendar year | | | January-June | |
| Item | 2021 | 2022 | 2023 | 2023 | 2024 |
| Purchases from U.S. importers of HECs from— Brazil | | | | | |
| China | | | | | |
| India | | | | | |
| Vietnam | | | | | |
| All subject sources | 0 | 0 | 0 | 0 | (|
| All other sources ¹ | | | | | |
| Purchases from domestic producers ² | | | | | |
| Purchases from other sources ³ | | | | | |
| Purchases from all sources | 0 | 0 | 0 | 0 | (|

² Please list the name of the U.S. producer(s) from which your firm purchased this product: _____.

³ Please list the name of the firm(s) from which your firm purchased this product: _____.

II-13. <u>Purchases of imports from subject sources</u>.--If your firm reported purchases from U.S. importers of HECs from Brazil, China, India, and Vietnam at any time since January 1, 2021, report those purchases by the individual importer of record and subject source.

Purchases of subject imports

| | Quantity (in 1,000 units) | | | | | | | | |
|--------------------|---------------------------|------|--------------|------|--------|--------|--|--|--|
| | | (| Calendar yea | r | Januar | y-June | | | |
| Importer of record | Subject source | 2021 | 2022 | 2023 | 2023 | 2024 | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| Grand total: | | 0 | 0 | 0 | 0 | 0 | | | |
| ษาสกับ เบเลา: | | U | U | U | U | U | | | |

II-13. Purchases of imports from subject sources.—Continued.

<u>RECONCILIATION OF PURCHASES FROM SUBJECT SOURCES</u>.--Please ensure that the quantities reported for your firms purchases of imports from subject sources reported in this question (i.e., "total purchases of imports from subject sources") in each time period equal the quantity reported for your firm's purchases from subject sources in each time period in the previous question. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

| | Calendar year | | | January-June | |
|-------------------------------------|---------------|------|------|--------------|------|
| Reconciliation | 2021 | 2022 | 2023 | 2023 | 2024 |
| Purchases from subject sources in | | | | | |
| this table – purchases from subject | | | | | |
| sources in previous table = zero | | | | | |
| ("0"), if not revise. | 0 | 0 | 0 | 0 | 0 |

II-14. Imports.--Since January 1, 2021, has your firm imported HECs?

"Importer" – The person or firm primarily liable for the payment of any duties on the merchandise, or an authorized agent acting on his behalf.

| No | Yes | |
|----|-----|---|
| | | If yes <u>COMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE</u> |

| II-15. | <u>Other explanations</u> If your firm would like to further explain a response to a question in Part II for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section. |
|--------|---|
| | |

SEC Forms 10-K / 10-Q

SEC Form 20-F Other (specify):

PART III.--FINANCIAL INFORMATION

Address questions on this part of the questionnaire to Jessica Lee (202-205-2055, Jessica, Lee@usitc.gov)

| Name | 2 | _ | | | | | | |
|-----------|--|---|--|-----------------|----------------|-----------|--|--|
| Title | | | | | | | | |
| Email | | | | | | | | |
| Telep | hone | | | | | | | |
| Αςςοι | unting system. —Briefly des | cribe your firm's | financial acco | ounting syste | m. | | | |
| A.1. | When does your firm's fi | scal vear end (mo | onth and dav) | ? | | | | |
| | If your firm's fiscal year o | | • • | | w: | | | |
| A.2. | Note: Calendar-year data | • | | • | | | | |
| | (i.e., in questions III-9a, III-9f, III-12a, and III-13a). However, if providing this data on a | | | | | | | |
| | <u>calendar-year basis is unduly burdensome or provides results that are not reliable,</u> <u>fiscal-year based data are acceptable.</u> Please indicate whether the results in this section | | | | | | | |
| | are provided on a calend | | | | | | | |
| | year) or on a fiscal-year I | • | _ | | • | a riscai | | |
| | <u>_</u> | | · · | | • | | | |
| | Calendar-year basis | Fiscal-year | basis (does r | not align with | the calenda | r year) | | |
| D 4 | Describe the lowest leve | • | | ision, compa | ny-wide) for | مام : مان | | |
| В.1. | | propored that inc | duda HECi | | | wnich | | |
| В.1. | financial statements are | prepared that inc | clude HEC: | | | wnich | | |
| | financial statements are Does your firm prepare p | orofit/loss statem | | | | wnich | | |
| | financial statements are | | | | | wnicn | | |
| B.1. B.2. | Does your firm prepare p | orofit/loss statem | ents for HEC: | | atements pre | | | |
| | financial statements are Does your firm prepare p | orofit/loss statem No and frequency (if | ents for HEC: | | atements pre | | | |
| B.2. | Does your firm prepare presses indicate the type | orofit/loss statem No and frequency (if | ents for HEC: | f financial sta | atements pre | | | |
| B.2. | Does your firm prepare pare yes Please indicate the type by your firm. Please check | orofit/loss statem No and frequency (if ck relevant items Check all | ents for HEC: applicable) o below. | f financial sta | uency Semi- | epared | | |
| B.2. | Does your firm prepare progressing the second statements are properly properly properly progressing the second statements are properly pro | orofit/loss statem No and frequency (if ck relevant items Check all | ents for HEC: | f financial sta | uency | | | |
| B.2. | Does your firm prepare progressing the type by your firm. Please check the type by a firm. Please check the type by your firm. | orofit/loss statem No and frequency (if ck relevant items Check all | ents for HEC: applicable) o below. | f financial sta | uency Semi- | epared | | |
| B.2. | Does your firm prepare progressing the second statements are properly properly properly progressing the second statements are properly pro | orofit/loss statem No and frequency (if ck relevant items Check all | ents for HEC: applicable) o below. | f financial sta | uency Semi- | epared | | |

B.4. Please indicate the primary accounting basis used by your firm.

| Accounting basis | Check one |
|------------------|-----------|
| U.S. GAAP | |
| IFRS | |
| Tax – cash | |
| Tax – accrual | |
| Other (specify): | |

| <u>Cost accounting system.</u> —Briefly describe your firm's cost accounting system (e.g., standard cost, job order cost, etc.). |
|--|
| |

III-4. **Product listing.**—Please list the products your firm produces in the facilities in which it produces HEC and provide the share of net sales accounted for by these products in 2023.

| Products | Share of sales in 2023 |
|----------|------------------------|
| HEC | % |
| | % |
| | % |
| | % |
| | % |

| or any ser | vices) use ns betwe | I suppliers.—Does your firm purchase inputs d in the production of HEC from any related en related firms, divisions and/or other com | suppliers (e.g., inclusive of |
|------------|------------------------|---|------------------------------------|
| | ? | | |
| YesCo | ontinue to | o question III-6. NoContinue to que | estion III-8a. |
| your firm | purchases | I suppliers.—Please identify the inputs used from related suppliers and that are reflecte se report this information by relevant input | d in question III-9a. For "Share |
| | | | Share of total |
| Input | | Related supplier | COGS in 2023 |
| | | | % |
| | | | % |
| | | | % |
| | | | % |
| | | Purchase cost valuation method | Check all that apply |
| Related s | supplier's | cost | |
| Cost plus | | | |
| Negotiat | ed transfe | er price to approximate fair market value | |
| Other (sp | ecify): | | |
| If the me | thods use | ed differ by input, please describe: | |
| purchased | I from rela | used for inputs from related suppliers.—Ple ated suppliers, as identified in III-6, were rep er consistent with the firm's accounting boo | orted in III-9a (financial results |
| | | If no—Provide an explanation and the valu | ation basis used for these input |
| Yes | No | in question III-9a. | |

III-8. Cost assignment/allocation basis.—Briefly describe the assignment/allocation bases used by your firm to assign the costs and expenses listed below for HECs in the normal course of business and in the financial results reported in question III-9a (e.g., actual costs, standard costs, percentage of COGS, percentage of sales, etc.).

| | Assignment/allocation bases used for HECs— | | | | |
|-----------------------|--|------------------------------------|--|--|--|
| Cost/expense | In the normal course of business | In the financial results at III-9a | | | |
| Raw materials | | | | | |
| Direct labor | | | | | |
| Other factory costs | | | | | |
| SG&A expenses | | | | | |
| Interest expense | | | | | |
| Other income/expenses | | | | | |

III-9a. <u>Operations on HECs</u>.—Report the revenue and related cost information requested below on the HEC operations of your firm's U.S. establishment(s). Include only sales (whether domestic or exports) and costs related to your U.S. manufacturing operations. <u>Do not</u> report any revenue or cost data related to the resale of purchased product.

Net sales—Report all commercial sales, internal consumption, and transfers to related firms, whether these are domestic sales or exports. Report net sales values less discounts, returns, allowances, and prepaid freight, in U.S. dollars, f.o.b. your point of shipment. The freight costs associated with delivering the product to your customer should not be included.

Note: If the financial data are reported on a calendar-year basis, the total net sales quantities and values should match the total shipment quantities and values reported in Part II of this questionnaire (see question III-14 for a reconciliation grid).

Internal consumption—Product consumed internally by your firm. Report internal consumption at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

Transfers to related firms—Sales made to related firms. Report transfers to related firms at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

Costs and expenses—Include costs and expenses associated with all reported net sales (i.e., for both domestic and export commercial sales, internal consumption, and transfers to related firms). If any freight costs were removed from net sales values, ensure the associated costs are removed from the applicable cost/expense line.

Inputs from related suppliers—Any inputs purchased from related suppliers should be reported in a manner consistent with your firm's accounting books and records.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the financial data, as Commission staff may contact your firm regarding questions on the financial data. The Commission may also request that your company submit copies of the supporting documents/records (financial statements, including internal profit-and-loss statements for the division or product group that includes HECs, as well as specific statements and worksheets) used to compile these data.

III-9a. **Operations on HECs**.—*Continued*

| Quantity (in 1,000 units) and value (in \$1,000) | | | | | | | |
|--|------|-------|------|---------|-------|--|--|
| | | Years | | January | -June | | |
| Item | 2021 | 2022 | 2023 | 2023 | 2024 | | |
| Net sales quantities: | | | | | | | |
| Commercial sales | | | | | | | |
| Internal consumption | | | | | | | |
| Transfers to related firms | | | | | | | |
| Total net sales quantities | 0 | 0 | 0 | 0 | 0 | | |
| Net sales values: Commercial sales | | | | | | | |
| Internal consumption | | | | | | | |
| Transfers to related firms | | | | | | | |
| Total net sales values | 0 | 0 | 0 | 0 | 0 | | |
| Cost of goods sold (COGS): Raw materials | | | | | | | |
| Direct labor | | | | | | | |
| Other factory costs | | | | | | | |
| Total COGS | 0 | 0 | 0 | 0 | 0 | | |
| Gross profit or (loss) | 0 | 0 | 0 | 0 | 0 | | |
| SG&A expenses | | | | | | | |
| Operating income (loss) | 0 | 0 | 0 | 0 | 0 | | |
| Other expenses and income: | | | | | | | |
| Interest expense | | | | | | | |
| All other expense items | | | | | | | |
| All other income items | | | | | | | |
| Net income or (loss) before | | | | | | | |
| income taxes | 0 | 0 | 0 | 0 | 0 | | |

III-9b. **Explanation of trends**.— Please indicate the primary decisions, events, or factors that impacted the trends in the following metrics reported in question III-9a.

| Metric | Explanation of trends |
|---|-----------------------|
| Net sales quantity | |
| Net sales values | |
| Raw material costs | |
| Direct labor costs | |
| Other factory costs | |
| SG&A costs | |
| Other expenses/income and interest expenses | |

III-9c. Financial data checklist.—

| Confirm the following with regard to the financial data reported in question III-9a: | √ if Yes |
|---|----------|
| In 1,000 units? | |
| In \$1,000 dollars (<i>not</i> actual dollars)? | |
| Include only the in-scope HEC? | |
| Net sales values (CS, IC, and/or Transfers) exclude freight costs associated with delivering the product to your customer(s), i.e., reflect f.o.b. values from your point of shipment? | |
| Net sales values (CS, IC, and/or Transfers) exclude all discounts, returns, allowances, and prepaid freight. | |
| Cost items (e.g., materials, labor, other factory costs, and/or SG&A) exclude freight costs associated with delivering the product to your customer(s)? | |
| If you did not v Yes in any of the boxes above, go back to III-9a and revise your response | nses. |

| III-9d. | <u>Financial data reconciliation</u> Certain line items from question III-9a, including total net sales |
|---------|---|
| | quantities and values, total COGS, gross profit (or loss), operating profit (or loss), and net |
| | income (or loss), have been calculated based on the data submitted for other line items. Are the |
| | data in these calculated line items correct according to your firm's financial records ignoring |
| | non-material differences that may arise due to rounding? |

| | | If noIf the calculated line items do not show the correct data, please double check the feeder data for data entry errors and revise. Also, check signs accorded to the post operating income line items. The two expense line items should report positive numbers (i.e., expenses are positive, and incomes or reversals are negative in these lines – instances of the latter should be rare in these lines). The income line item should also, in most instances, be a positive number (i.e., income is positive, and expenses or reversals are negative in this line). If, after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated line |
|-----|----|---|
| Yes | No | items persist, please identify and discuss the differences in the space below. |
| | | |

| III-9e. | Raw materials.—Please report the share of total raw material costs in 2023 (reported in III-9a |
|---------|--|
| | for the following raw material inputs: |

| | | | | | | Pro | ocureme | ent method |
|---------|---|----------------|----------------|------|------------------------------------|-------------|------------|-------------------------------|
| | | | | Sha | re of total ra | w Prim | arily | Primarily |
| | | | | m | aterial costs | - | ced by | purchased by |
| - | | Input | | | (percent) | your | firm | your firm |
| | Gelatin | | | | | | | |
| _ | HPMC | | | | | | | |
| _ | Pullulan | | | | | | | |
| | Other raw m | aterial inputs | s ¹ | | | | | |
| | Total (sho | uld sum to 1 | 00 percent |) | (| 0.0 | | |
| | ¹ If there a category, plea account: | | - | | puts included e of the total ra | | | • |
| | Depreciation within the re | | | | • | ation exper | F | |
| | | | | | Years | | - | nuary-June |
| | | Item | | 2021 | 2022 | 2023 | 202 | 3 2024 |
| | Depreciatio | n expense (ii | 1 \$1,000) | | | | | |
| III-9g. | Depreciation (e.g., other faabove. | - | | | | | • | stion III-9a ense reported |
| | | | | | | | | |
| III-9h. | Regulatory c | • | • | | January 1, 2 | 021, did yo | ur firm ir | ncur costs |
| | | | | | | | | |

III-10a. Nonrecurring items (charges and gains) included in the HECs financial results.—Please report all material (significant) nonrecurring items (charges and gains) that are included in the reported results at question III-9a. If a nonrecurring item that is not product-specific was allocated to the results at question III-9a, please report the allocated value, below, rather than the aggregate amount.

Note: The Commission's objective here is to gather information on <u>material (significant)</u> nonrecurring items which impacted the reported financial results for HECs in question III-9a.

| | | Years | | Januar | y-June |
|---------------------|------|-------|--------------------------|--------|--------|
| Item | 2021 | 2022 | 2023 | 2023 | 2024 |
| | | | Value (<i>\$1,000</i>) | | |
| Nonrecurring item 1 | | | | | |
| Nonrecurring item 2 | | | | | |
| Nonrecurring item 3 | | | | | |
| Nonrecurring item 4 | | | | | |
| Nonrecurring item 5 | | | | | |
| Nonrecurring item 6 | | | | | |
| Nonrecurring item 7 | | | | | |

III-10b. Nonrecurring items (charges and gains) included in the HECs financial results.—In this table, please provide a brief description of each nonrecurring item reported above and indicate the specific line item within question III-9a in which the nonrecurring item is classified.

| | Description of the nonrecurring item | Location (i.e., line item) within question III-9a |
|---------------------|--------------------------------------|--|
| Nonrecurring item 1 | | |
| Nonrecurring item 2 | | |
| Nonrecurring item 3 | | |
| Nonrecurring item 4 | | |
| Nonrecurring item 5 | | |
| Nonrecurring item 6 | | |
| Nonrecurring item 7 | | |

| III-11. | Classification of identified nonrecurring items (charges and gains) in the accounting books and |
|---------|---|
| | records of the company.—If non-recurring items were reported in question III-10 above, please |
| | identify where your company recorded these items in your accounting books and records in the |
| | normal course of business, just as responses to question III-10 identify the specific line items in |
| | question III-9a where these items are reported. |
| | |

| II C D | roducars' | Questionnaire | - Hard Empty | Canculas | (Draliminary) |
|--------|-----------|---------------|--------------|----------|---------------|
| U.S. P | roducers | Questionnaire | - mara embly | Cabsules | i Preliminary |

III-12a. <u>Asset values</u>.—Report the total assets (i.e., <u>both current and long-term assets</u>) associated with the production, warehousing, and sale of HEC. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for HEC in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with relevant cost allocations used in question III-9a.

Note: Total assets should reflect the <u>net amount of assets</u> (i.e., after any accumulated depreciation and allowances deducted) and should be <u>allocated to HEC</u> if these assets are also related to other products. **DO NOT INCLUDE LIABILITIES.**

| | Value (in \$ | 51,000) | |
|--------------------|--------------|---------|------|
| | | Years | |
| Item | 2021 | 2022 | 2023 |
| Total assets (net) | | | |

| II-13a. | Canital expanditures and | rocoarch and do | volonment (" | 'Be D") aynan | sas Donort | vour firm's |
|---------|---|-----------------|--------------------------|---------------|--------------|-------------|
| II-13a. | Capital expenditures and recapital expenditures and re | | | | | your firm's |
| | | Val | ue (<i>in \$1,000</i>) |) | | |
| | | | Years | | Januai | ry-June |
| | Item | 2021 | 2022 | 2023 | 2023 | 2024 |
| | Capital expenditures | | | | | |
| | R&D expenses | | | | | |
| | | | | | ture focus a | |
| II-13b. | Description of reported cap significance of your firm's re reported, please explain the | eported capital | | | | |
| II-13b. | significance of your firm's re | eported capital | | | | |

III-14a. <u>Data consistency and reconciliation</u>.—The quantities and values of total net sales reported in question III-9a should reconcile with the total shipments reported in question II-8 (including export shipments) for the annual-year periods as long as they are reported on the same calendar-year basis. The interim-period data should reconcile whether the financial data are on a calendar- or fiscal-year basis.

If the calculated fields below return values other than zero (i.e., "0") this indicates the total net sales quantities and values do not match the total shipments quantities and values.

| | Years | | | January-June | |
|---|-------|------|------|--------------|------|
| Reconciliation | 2021 | 2022 | 2023 | 2023 | 2024 |
| Quantity: Trade data from question II-8 (lines D, F, H, and J) less financial total net sales quantity data from question III-9a, = zero ("0"). | 0 | 0 | 0 | 0 | 0 |
| Value: Trade data from question II-8 (lines E, G, I, and K) less financial total net sales value data from question III-9a, = zero ("0"). | 0 | 0 | 0 | 0 | 0 |

| Is the financial data in question III-9a reported on a calendar-year basis? | | | | | | | | | |
|--|-----|----|------------------------|--|--|--|--|--|--|
| Yes—Complete question III-14b. No— Continue to question III-15. | | | | | | | | | |
| III-14b. Data consistency and reconciliation (calendar-year based financial data).—Do the data in question III-9a reconcile with the data in question II-8 (i.e., the calculated fields are returning zeros in the table above) for all periods? | | | | | | | | | |
| | Yes | No | If no, please explain. | | | | | | |
| | | | | | | | | | |

If your responses to any of the items in questions III-15, III-16, and III-17 differ by country, please describe these differences and, as applicable, indicate which country or countries your response refers to in the relevant form fields.

III-15. <u>Effects of imports on investment</u>.—Since January 1, 2021, has your firm experienced any actual negative effects on its return on investment or the scale of capital investments as a result of imports of HEC from Brazil, China, India and Vietnam?

| | 1 | 1 | |
|----|--|--|--|
| No | Yes | | |
| | | If yes, my firm has experien | nced actual negative effects as follows: |
| | (chec | k as many as appropriate) | (please describe) |
| | | Cancellation, postponement, or rejection of expansion projects | |
| | Denial or rejection of investment proposal Reduction in the size of capital investments Return on specific investments negatively impacted | | |
| | | | |
| | | | |
| | | Other | |

| III-16. | Effects of imports on growth and development.—Since January 1, 2021, has your firm |
|---------|--|
| | experienced any actual negative effects on its growth, ability to raise capital, or existing |
| | development and production efforts (including efforts to develop a derivative or more advanced |
| | version of the product) as a result of imports of HECs from Brazil, China, India and Vietnam? |

| | · | , | |
|----|-------|---|--|
| No | Yes | | |
| | | If yes, my firm has experier | nced actual negative effects as follows: |
| | | | |
| | (chec | ck as many as appropriate) | (please describe) |
| | | Rejection of bank loans | |
| | | Lowering of credit rating | |
| | | Problem related to the issue of stocks or bonds | |
| | | Ability to service debt | |
| | | Other | |

| U.S. Pro | oducers' Qu | estionnai | re - Hard Empty Capsules (Preliminary) | Page 39 | | |
|----------|--|------------|--|---------|--|--|
| III-17. | 7. Anticipated effects of imports.—Does your firm anticipate any negative effects due to imports of HEC from Brazil, China, India and Vietnam? | | | | | |
| | No | Yes | If yes, my firm anticipates negative effects as follows: | | | |
| | | | | | | |
| III-18. | Effects on financial performance of COVID-19.—Has the COVID-19 pandemic, or any government actions taken to contain the spread of the COVID-19 virus, affected the financial performance of your firm's operations on HEC as reported in question III-9a? In your response, please include the duration and timing of any impacts as they relate to your firm's financial performance. | | | | | |
| | No | Yes | If yes, please describe these effects. | | | |
| | | | | | | |
| III-19. | III for which | h a narrat | .—If your firm would like to further explain a response to a question tive box was not provided, please note the question number and the pace provided below. Please also use this space to highlight any issue. | е | | |

firm had in providing the data in this section.

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Amelia Preece (202-205-3250, amelia.preece@usitc.gov).

IV-1. <u>Contact information</u>.--Please identify the individual that Commission staff may contact regarding the confidential information submitted in Part IV.

| Name | |
|-----------|--|
| Title | |
| Email | |
| Telephone | |

PRICE DATA

- IV-2. This question requests quarterly quantity and value data for your firm's commercial shipments to unrelated U.S. customers since January 1, 2021 of the following products produced by your firm.
 - **Product 1.--** Hard empty gelatin capsules (including cap and body) for human consumption, in all sizes between 00 to 3 (whether regular, elongated, or enrobing), imprinted, and sold in per 1,000 unit increments.
 - **Product 2.-**-Hard empty gelatin capsules (including cap and body) for human consumption, in all sizes between 00 to 3 (whether regular, elongated, or enrobing), **NOT** imprinted, and sold in per 1,000 unit increments.
 - **Product 3.--**Hard empty hydroxypropyl methylcellulose ("HPMC") capsules (including cap and body) for human consumption, in all sizes between 00 to 3 (whether regular, elongated, or enrobing), imprinted, and sold in per 1,000 unit increments.
 - **Product 4.--**Hard empty hydroxypropyl methylcellulose ("HPMC") capsules (including cap and body) for human consumption, in all sizes between 00 to 3 (whether regular, elongated, or enrobing), **NOT** imprinted, and sold in per 1,000 unit increments.

Please note that values should be <u>f.o.b.</u>, <u>U.S.</u> <u>point of shipment</u> and should not include U.S.-inland transportation costs. Values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates).

IV-2a. During January-June 2024, did your firm produce and sell to unrelated U.S. customers any of the above listed products (or any products that were competitive with these products)?

| YesPlease complete the following pricing data table as appropriate. |
|---|
| NoSkip to question IV-3. |

Product 2: Product 3: Product 4:

IV-2b. <u>Price data</u>.--Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

Report data in 1,000 units and actual dollars (not \$1,000s).

| | | (Quant | ity <i>in 1,000 ui</i> | nits, value | in dollars) | | | |
|--|--|--|--|--------------------------------|-------------------|---------------|-----------|-------|
| | Product 1 | | Product 2 | | Product 3 | | Product 4 | |
| Period of shipment | Quantity | Value | Quantity | Value | Quantity | Value | Quantity | Value |
| 2021: | | | | | | | | |
| January-March | | | | | | | | |
| April-June | | | | | | | | |
| July-September | | | | | | | | |
| October- | | | | | | | | |
| December | | | | | | | | |
| 2021: | | | | | | | | |
| January-March | | | | | | | | |
| April-June | | | | | | | | |
| July-September | | | | | | | | |
| October- | | | | | | | | |
| December | | | | | | | | |
| 2023: | | | | | | | | |
| January-March | | | | | | | | |
| April-June | | | | | | | | |
| July-September | | | | | | | | |
| October- | | | | | | | | |
| December | | | | | | | | |
| 2024: | | | | | | | | |
| January-March | | | | | | | | |
| April-June | | | | | | | | |
| ¹ Net values (i.e., gros firm's U.S. point of shipmer ² Pricing product defin Note -If your firm's product of your firm's product. Also | nt. Please subtra nitions are provic ct does not exact | ct any discou led on the firs tly meet the p | nts, rebates, and st page of Part IV product specifica | returns from . tions but is co | the quarter in wo | hich the sale | occurred. | · |
| | , piease explain | any anomalie | s iii your iiiill S f | eporteu prici | iig udld. | | | |
| Product 1: | | | | | | | | |

| IV-2c. | Price data checklist Please check that the pricing data in question IV-2b have been correctly |
|--------|---|
| | reported. |

| | Are the price data reported above: | √ if Yes | | | | |
|--------|--|----------|--|--|--|--|
| | In actual dollars (not \$1,000s) and 1,000 units (capsules)? | | | | | |
| | Valued f.o.b. U.S. point of shipment (i.e., exclude U.S. inland transportation costs)? | | | | | |
| | Reported net of all discounts, rebates, and returns (deducted from the quarter in which the original sale occurred)? | | | | | |
| | Reported for commercial U.S. shipments only (i.e., exclude internal consumption, transfers, and exports)? | | | | | |
| | Less than or equal to the quantities and values reported in Part II for commercial U.S. shipments in each period? | | | | | |
| | Explanation(s) for any boxes not checked: | | | | | |
| IV-2d. | Pricing data methodologyPlease describe the method and the kinds of documents/that were used to compile your price data. | records | | | | |
| | | | | | | |

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the price data, as Commission staff may contact your firm regarding questions on the price data. The Commission may also request that your company submit copies of the supporting documents/records (such as sales journal, invoices, etc.) used to compile these data.

| IV-3. | Price settingHow does your firm determine the prices that it charges for sales of HECs (check |
|-------|---|
| | all that apply)? |

| Transaction by transaction | Contracts | Set price lists | Other | If other, describe |
|----------------------------------|-----------|-----------------------|-------|--------------------|
| | | | | |

IV-4. <u>Discount policy</u>.--Please indicate and describe your firm's discount policies (*check all that apply*).

| Quantity discounts | Annual total volume discounts | No discount policy | Other | Describe |
|-----------------------|--|--------------------------|-------|----------|
| | | | | |

IV-5. **Pricing terms.--**On what basis are your firm's prices of domestic HECs usually quoted *(check one)*?

| Delivered | F.o.b. | If f.o.b., specify point |
|-----------|--------|--------------------------|
| | | |

IV-6. <u>Contract versus spot</u>.--Approximately what shares of your firm's sales of its U.S.-produced HECs in 2023 were on the basis of (1) short-term contracts, (2) annual contracts, (3) long-term contracts, and (4) spot sales?

| | | Туре о | f sale | | | |
|---------------------|---|--|--|---|-------------------------------------|--------|
| ltem | Short-term contracts (multiple deliveries for less than 12 months) | Annual contracts (multiple deliveries for 12 months) | Long-term contracts (multiple deliveries for more than 12 months) | Spot sales (for a single delivery) | Total (shoul sum to 100.0% | d o |
| Share of 2023 sales | % | % | % | % | 0.0 | % |

IV-7. <u>Contract provisions.</u>--Please fill out the table regarding your firm's typical sales contracts for U.S.-produced HECs (or check "not applicable" if your firm does not sell on a short-term, annual and/or long-term contract basis).

| Typical sales contract provisions | Item | Short-term contracts (multiple deliveries for less than 12 months) | Annual contracts (multiple deliveries for 12 months) | Long-term contracts (multiple deliveries for more than 12 months) |
|-------------------------------------|----------------|---|---|--|
| Average contract duration | No. of days | | 365 | |
| Price renegotiation | Yes | | | |
| (during contract period) | No | | | |
| | Quantity | | | |
| Fixed quantity and/or price | Price | | | |
| 3.1.5, 5.1 p.1.55 | Both | | | |
| Indexed to raw | Yes | | | |
| material costs ¹ | No | | | |
| Not applicab | le | | | |
| ¹ Please identify the in | idexes used: | | | |

IV-8. <u>Lead times.--</u>What share of your firm's sales of its U.S.-produced HECs was from inventory and produced to order, and what was the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced HECs?

| Source | Share of 2023 sales | Lead time (Average number of days) |
|------------------------------|---------------------|------------------------------------|
| From inventory | % | |
| Produced to order | % | |
| Total (should sum to 100.0%) | 0.0 % | |

| IV-9. | <u>Shippi</u> | ng information |
|-------|---------------|--|
| | (a) | Who generally arranges the transportation to your firm's customers' locations? |

☐ Your firm ☐ Purchaser (check one)

(b) Indicate the approximate percentage of your firm's sales of HECs that are delivered the following distances from its production facility.

| Distance from production facility | Share |
|-----------------------------------|-------|
| Within 100 miles | % |
| 101 to 1,000 miles | % |
| Over 1,000 miles | % |
| Total (should sum to 100.0%) | 0.0 % |

IV-10. <u>Geographical shipments.--</u>In which U.S. geographic market area(s) has your firm sold its U.S.-produced HECs since January 1, 2021 (check all that apply)?

| Geographic area | √ if applicable |
|--|-----------------|
| NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT. | |
| Midwest.–IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI. | |
| Southeast.—AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV. | |
| Central Southwest.—AR, LA, OK, and TX. | |
| Mountains.–AZ, CO, ID, MT, NV, NM, UT, and WY. | |
| Pacific Coast.–CA, OR, and WA. | |
| Other.—All other markets in the United States not previously listed, including AK, HI, PR, and VI. | |

| IV-11. | <u>Inland transportation costs.</u> —What is the approximate percentage | of the cost of U.Sproduced |
|--------|---|----------------------------|
| | HECs that is accounted for by U.S. inland transportation costs? | percent |

IV-12. <u>End uses.--</u>List the end uses of the HECs that your firm manufactures. For each end-use product, what percentage of the <u>total cost</u> is accounted for by HECs and other inputs?

| | | t of end use product ted for by | Total |
|-----------------|------|------------------------------------|----------------|
| | | | (should sum to |
| End-use product | HECs | Other inputs | 100.0% across) |
| | % | % | 0.0 % |
| | % | % | 0.0 % |
| | % | % | 0.0 % |

| | | | | | На | | | ice of this substitu | ute |
|------------------------|---|--|--|---------------------------------------|---------------------------------------|-------------------------|---|--|-----|
| | Substitute | E | ind use in w substitute | | No | Yes | affected the pri | planation | |
| 1. | | | | | | | | <u>.</u> | |
| 2. | | | | | | | | | |
| | | | | | | _ | | | |
| 3. IV-14. | known) for F ended lower | IECs steadil , or steadil | ly increased, y decreased | , fluctuate since Jan | ed but en uary 1, 2 | ded h 021? | nigher, not chan Explain any trer | e United States (if ged, fluctuated bu nds and describe tl | |
| | known) for F ended lower principal fac | IECs steadil , or steadily ors that ha | ly increased, y decreased ave affected | , fluctuate since Jan these cha | ed but en uary 1, 2 anges in c | ided h 021? demai | nigher, not chan Explain any trer nd. | ged, fluctuated bu | |
| IV-14. | known) for Hended lower principal fact per row. | IECs steadil , or steadil | ly increased, y decreased | , fluctuate since Jan these cha | ed but en uary 1, 2 | ided h 021? demai | nigher, not chan Explain any trer | ged, fluctuated bu | he |
| IV-14. ect one box Mar | known) for Hended lower principal fact per row. | IECs steadil, or steadily cors that ha | ly increased y decreased ave affected | , fluctuate since Jan these cha | ed but en uary 1, 20 anges in c | ided h 021? demai | nigher, not chan Explain any tren nd. Steadily | ged, fluctuated bunds and describe the | he |

| | No | Yes | If yes, pleas | se describe | , including a | ny changes since January 1, 2021. |
|----|--|---|--|--|---|---|
| | | | , ,, | | | |
| 7. | | | | | - | to conditions of competition distinctive previous question? If yes, describe. |
| | No | Yes | If yes, pleas | se describe | , including a | ny changes since January 1, 2021. |
| | | | | | | |
| 3. | since Janu entry," de quantity p | ary 1, 2021 clining to a romised, b | 1 (examples accept new opeing unable | include pla customers o to meet tii | cing custom or renew exi | been unable to supply HECs at any time ers on allocation or "controlled order sting customers, delivering less than the ent commitments, impact from changes |
| 3. | since Janu entry," de quantity p | ary 1, 202: clining to a romised, b ons listed i | 1 (examples accept new opeing unable n II-2a, etc.) | include pla customers on to meet tii ? | icing custom or renew exi mely shipme | ers on allocation or "controlled order sting customers, delivering less than the |
| 8. | since Janu entry," de quantity p in operatio | ary 1, 202: clining to a romised, b ons listed i | 1 (examples accept new opeing unable n II-2a, etc.) If yes, pleas | include pla customers on to meet tii ? | icing custom or renew exi mely shipme | ers on allocation or "controlled order sting customers, delivering less than the int commitments, impact from changes |
| | since Janu entry," de quantity p in operation No Raw mate not change | ary 1, 202: clining to a romised, b ons listed i Yes rials Haved, fluctua | 1 (examples accept new opeing unable n II-2a, etc.) If yes, pleas constraint. Ve HECs raw ted but end | include pla customers of to meet til ? se describe | cing custom or renew eximely shipme , including the | ers on allocation or "controlled order sting customers, delivering less than the int commitments, impact from changes |
| 9. | since Janu entry," de quantity p in operatio | rials Haved, fluctuate box per ro | 1 (examples accept new opeing unable n II-2a, etc.) If yes, please constraint. We HECs raw ted but end ow. | include pla customers of to meet til ? se describe | cing custom or renew eximely shipme , including the | ers on allocation or "controlled order sting customers, delivering less than the ent commitments, impact from changes he reason, timing, and duration of the vincreased, fluctuated but ended higher, |

IV-20. <u>Interchangeability</u>.—How often is HECs produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = *no familiarity* with products from a specified country-pair

| Country-pair | Brazil | China | India | Vietnam | Other countries |
|---------------|--------|-------|-------|---------|-----------------|
| United States | | | | | |
| Brazil | | | | | |
| China | | | | | |
| India | | | | | |
| Vietnam | | | | | |

For any country-pair producing HECs that is *sometimes* or *never* interchangeable, identify the country-pair and explain the factors that limit or preclude the interchangeable use of HECs produced in the countries:

| U.S. | Producers' | Questionnaire - | Hard Empty | Capsules | (Preliminary) |
|------|------------|-----------------|-------------------|----------|---------------|
|------|------------|-----------------|-------------------|----------|---------------|

IV-21. <u>Factors other than price</u>.—How often are differences other than price (e.g., quality, availability, transportation network, product range, technical support, *etc.*) between HECs produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = no familiarity with products from a specified country-pair

| Country-pair | Brazil | China | India | Vietnam | Other countries |
|---|--------|-------|--------------|---------|-----------------|
| United States | | | | | |
| Brazil | | | | | |
| China | | | | | |
| India | | | | | |
| Vietnam | | | \backslash | | |
| For any country-pair for which factors other than price are <i>always</i> or <i>frequently</i> a significant factor in your firm's sales of HECs, identify the country-pair and the relevant factors other than price, and report the advantages or disadvantages imparted by such factors: | | | | | |

IV-22. Role of section 301 tariffs.-- Did the tariffs on Chinese-origin products under section 301, or changes in these tariffs, have an impact on the HECs market in the United States, including any effects on HECs cost, price, supply, and/or demand, since January 1, 2021?

| If yes, please describe the impact on cost, price, supply, and/or demand, and include the timing of such impacts. | |
|---|--|
| | |

IV-23. <u>Customer identification.</u>--List the names and contact information for your firm's 10 largest U.S. customers for HECs since January 1, 2021. Indicate the share of the quantity of your firm's U.S. shipments of HECs that each of these customers accounted for in 2023.

| Cu | stomer's name | Contact person | Email | Telephone | City | State | Share of 2023 sales (%) |
|----|---------------|----------------|-------|-----------|------|-------|-------------------------------------|
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | | |
| 5 | | | | | | | |
| 6 | | | | | | | |
| 7 | | | | | | | |
| 8 | | | | | | | |
| 9 | | | | | | | |
| 10 | | | | | | | |

| U.S. | Producers' | Questionnaire - | Hard Empty | Capsules | (Preliminary) |) |
|------|------------|-----------------|-------------------|-----------------|---------------|---|
|------|------------|-----------------|-------------------|-----------------|---------------|---|

| IV-24. | Com | petition | from | imports. | |
|--------|-----|----------|------|----------|--|
|--------|-----|----------|------|----------|--|

| (a) | <u>Lost revenue</u> Since January 1, 2021: To avoid losing sales to competitors selling HECs |
|-----|--|
| | from Brazil, China, India, and Vietnam, did your firm: |

| Item | No | Yes |
|-------------------------------------|----|-----|
| Reduce prices | | |
| Roll back announced price increases | | |

(b) <u>Lost sales.</u>--Since January 1, 2021: Did your firm lose sales of HECs to imports of this product from Brazil, China, India, and Vietnam?

| No | Yes |
|----|-----|
| | |

(c) The submission of lost sales/lost revenue allegations is to be completed only by NON-PETITIONERS.

If your firm indicated "yes" to any of the above, your firm can provide the Commission with additional information by downloading and completing the lost sales/lost revenues worksheet at http://usitc.gov/trade_remedy/question.htm. Note that the Commission may contact the firms named to verify the allegations reported.

Is your firm submitting the lost sales/lost revenues worksheet?

| No—Please explain. |
|--|
| Yes—Please complete the worksheet and submit via the Commission dropbox. https://dropbox.usitc.gov/oinv/ . (select Lost Sales-Lost Revenues) |

| IV-25. | Other explanationsIf your firm would like to further explain a response to a question in Part |
|--------|---|
| | IV for which a narrative response box was not provided, please note the question number and |
| | the explanation in the space provided below. Please also use this space to highlight any issues |
| | your firm had in providing the data in this section. |

HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://usitc.gov/reports/active import injury questionnaires.

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission of further instructions.

• <u>Upload via Commission's secure submission portal</u>.— The questionnaire must be uploaded in two formats: (1) a Microsoft Word 97-2003 document; and (2) a PDF copy of the complete questionnaire with a signature on the first page. Please include any attachments at the end of the PDF (e.g., APO certification, additional comments, etc.).

Web address: https://usitc.gov/qportal Pin: HECS Phase: Preliminary

• E-mail.— E-mail the MS Word questionnaire to <u>julie.duffy@usitc.qov</u>; include a PDF copy of the complete questionnaire with a signature on the first page. Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure submission portal and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm does not produce this product, please fill out page 1, print, sign, and submit a scanned PDF copy via the Commission's secure submission portal or email.

<u>Parties to this proceeding</u>.— If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1802). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.